- Perceptron (NASDAQ:PRCP) -15%.
- Zynex (NASDAQ:ZYXI) -12% after pricing equity offering.
- Rigel Pharmaceuticals (NASDAQ:RIGL) -11%.
- Cleveland BioLabs (NASDAQ:CBLI) -9%.
- INmune Bio (NASDAQ:INMB) -9%.
- VolitionRx (NYSEMKT:VNRX) -9%.
- IMV (NASDAQ:IMV) -8%.
- WiMi Hologram Cloud (NASDAQ:WIMI) -8%.
- Boxlight (NASDAQ:BOXL) -7%.
- ElectroCore (NASDAQ:ECOR) -7% on preliminary Q2 revenue.
- Iconix Brand Group (NASDAQ:ICON) -7%.
- Caladrius Biosciences (NASDAQ:CLBS) -7%.
- Equillium (NASDAQ:EQ) -6%.
- Dare Bioscience (NASDAQ:DARE) -5%.